Author

Luba Benimetskaya

Observed name: LUBA BENIMETSKAYA

Institutions: Albert Einstein College of Medicine, City Of Hope National Medical Center, Montefiore Medical Center, Yeshiva University, Johns Hopkins Medicine, Montefiore Einstein Comprehensive Cancer Center

Observed institutions: Albert Einstein College of Medicine, City Of Hope National Medical Center, United States Food and Drug Administration, Montefiore Medical Center, Johns Hopkins University, The University of Melbourne, Yeshiva University, Florey Institute of Neuroscience and Mental Health, Johns Hopkins Medicine, Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk, Montefiore Einstein Comprehensive Cancer Center, Columbia University, Polish Academy of Sciences

OpenAlex ID: A5113666686

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

2009 · C. A. Stein, J. Bo Hansen, et al. · Nucleic Acids Research · 393

PDF

A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC

2006 · Johnathan C. Lai, Wenzhi Tan, et al. · Proceedings of the National Academy of Sciences · 87

Inhibition of Potentially Anti-Apoptotic Proteins by Antisense Protein Kinase C-α (Isis 3521) and Antisense bcl-2 (G3139) Phosphorothioate Oligodeoxynucleotides: Relationship to the Decreased Viability of T24 Bladder and PC3 Prostate Cancer Cells

2001 · Luba Benimetskaya, Paul Miller, et al. · Molecular Pharmacology · 59

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

2008 · Luba Benimetskaya, Sijian Wu, et al. · Blood · 58

PDF

Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Veno-occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action

2006 · Noah Kornblum, Kanyalakshmi Ayyanar, et al. · Oligonucleotides · 49

G3139 and Other CpG-Containing Immunostimulatory Phosphorothioate Oligodeoxynucleotides Are Potent Suppressors of the Growth of Human Tumor Xenografts in Nude Mice

2006 · Volker Gekeler, Petra Gimmnich, et al. · Oligonucleotides · 47

G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.

2003 · Jonathan C Lai, Luba Benimetskaya, et al. · PubMed · 47

Antisense RNA Down-Regulation of bcl-2 Expression in DU145 Prostate Cancer Cells Does Not Diminish the Cytostatic Effects of G3139 (Oblimersen)

2004 · Anthony Raffo, Johnathan C. Lai, et al. · Clinical Cancer Research · 45

Antisense Strategies for Oncogene Inactivation

2005 · C.A. Stein, Luba Benimetskaya, et al. · Seminars in Oncology · 44

Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.

2002 · Maria Vilenchik, Anthony J Raffo, et al. · PubMed · 42

Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells

2005 · Johnathan C. Lai, Luba Benimetskaya, et al. · Molecular Cancer Therapeutics · 35

PDF

Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells

2004 · Luba Benimetskaya, Johnathan C. Lai, et al. · Clinical Cancer Research · 32

Changes in Gene Expression Induced by Phosphorothioate Oligodeoxynucleotides (Including G3139) in PC3 Prostate Carcinoma Cells Are Recapitulated at Least in Part by Treatment with Interferon-β and -γ

2004 · Luba Benimetskaya, Timo Wittenberger, et al. · Clinical Cancer Research · 28

PDF

Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro

2006 · Luba Benimetskaya, Kanyalakshmi Ayyanar, et al. · Clinical Cancer Research · 26

Protamine-Fragment Peptides Fused to an SV40 Nuclear Localization Signal Deliver Oligonucleotides That Produce Antisense Effects in Prostate and Bladder Carcinoma Cells

2002 · Luba Benimetskaya, Nancy Guzzo-Pernell, et al. · Bioconjugate Chemistry · 24

G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, AltersIn vitroEndothelial Cell Growth and Tubular Morphogenesis

2009 · C.A. Stein, SiJian Wu, et al. · Clinical Cancer Research · 21

Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy

2006 · Hong Zhao, Ping Peng, et al. · Journal of Controlled Release · 21

Comparison of D-G3139 and Its Enantiomer L-G3139 in Melanoma Cells Demonstrates Minimal In Vitro but Dramatic In Vivo Chiral Dependency

2007 · Johnathan C Lai, Bob D Brown, et al. · Molecular Therapy · 13

PDF

Antisense Therapy: Recent Advances and Relevance to Prostate Cancer

2002 · Luba Benimetskaya, C.A. Stein · Clinical Prostate Cancer · 11

Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.

2006 · Constantine S. Mitsiades, Luba Benimetskaya, et al. · Blood · 5

Induction of Apoptosis by G3139 in Melanoma Cells

2005 · LUBA BENIMETSKAYA, JOHNATHAN C. LAI, et al. · Annals of the New York Academy of Sciences · 5

518A2 Melanoma Cells Are Protected by G3139 and Other Antineoplastic Agents Against the Cytotoxic Effects of DTIC

2005 · Luba Benimetskaya, Paul Miller, et al. · Oligonucleotides · 5

Combinations of Chemotherapy and G3139, an Antisense Bcl-2 Oligonucleotide

2005 · Luba Benimetskaya, Sridhar Mani, et al. · Humana Press eBooks · 1

Inhibition of Bcl-2 by Anti-Sense Oligonucleotide and siRNA in Specimens from Patients with Waldenström’s Macroglobulinemia (WM).

2004 · Gwen L. Nichols, Luba Benimetskaya, et al. · Blood · 1

Genasense (G3139): An Antisense Bcl-2 Oligodeoxyribonucleotide with Substantial Clinical Activity and a Complex Mechanism of Action

2008 · Cy A. Stein, Noah Kornblum, et al. · Royal Society of Chemistry eBooks

Works count: 26

Citation count: 1,099

H-index: 17

I10-index: 19